SG11202112762TA - Multispecific transthyretin immunoglobulin fusions - Google Patents

Multispecific transthyretin immunoglobulin fusions

Info

Publication number: SG11202112762TA
Authority: SG; Singapore
Prior art keywords: transthyretin; multispecific; immunoglobulin fusions; fusions; immunoglobulin
Prior art date: 2019-07-08

Application number

SG11202112762TA

Inventor

Kenneth William Walker

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-07-06Application filed by Amgen IncfiledCriticalAmgen Inc

2021-12-30Publication of SG11202112762TApublicationCriticalpatent/SG11202112762TA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SG11202112762TA2019-07-082020-07-06Multispecific transthyretin immunoglobulin fusionsSG11202112762TA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201962871247P	2019-07-08	2019-07-08
PCT/US2020/040873WO2021007150A1 (en)	2019-07-08	2020-07-06	Multispecific transthyretin immunoglobulin fusions

Publications (1)

Publication Number	Publication Date
SG11202112762TAtrue SG11202112762TA (en)	2021-12-30

Family

ID=71784719

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202112762TASG11202112762TA (en)	2019-07-08	2020-07-06	Multispecific transthyretin immunoglobulin fusions

Country Status (10)

Country	Link
US (1)	US20220324924A1 (en)
EP (1)	EP3997112A1 (en)
JP (1)	JP7695925B2 (en)
KR (1)	KR20220032065A (en)
CN (1)	CN114127125B (en)
AU (1)	AU2020310851A1 (en)
CA (1)	CA3140208A1 (en)
MX (1)	MX2021015976A (en)
SG (1)	SG11202112762TA (en)
WO (1)	WO2021007150A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2019070901A1 (en)	2017-10-04	2019-04-11	Amgen Inc.	Transthyretin immunoglobulin fusions
EP4234695A1 (en)*	2022-02-24	2023-08-30	Sartorius BIA Separations d.o.o.	Methods for the selective removal of contaminants during a process of purifying biologic agents

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4447A (en)		1846-04-04		Car- wheel
US233A (en)		1837-06-14		Improvement in plows
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4475196A (en)	1981-03-06	1984-10-02	Zor Clair G	Instrument for locating faults in aircraft passenger reading light and attendant call control system
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
US4439196A (en)	1982-03-18	1984-03-27	Merck & Co., Inc.	Osmotic drug delivery system
US4447224A (en)	1982-09-20	1984-05-08	Infusaid Corporation	Variable flow implantable infusion apparatus
US4487603A (en)	1982-11-26	1984-12-11	Cordis Corporation	Implantable microinfusion pump system
US4486194A (en)	1983-06-08	1984-12-04	James Ferrara	Therapeutic device for administering medicaments through the skin
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en)	1983-11-01	1986-10-07	Terumo Kabushiki Kaisha	Pharmaceutical composition containing urokinase
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
DE3785186T2 (en)	1986-09-02	1993-07-15	Enzon Lab Inc	BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN.
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
US20030191056A1 (en)	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20080311078A1 (en)	2005-06-14	2008-12-18	Gokarn Yatin R	Self-Buffering Protein Formulations
PL2975051T3 (en)	2009-06-26	2021-09-20	Regeneron Pharmaceuticals, Inc.	Readily isolated bispecific antibodies with native immunoglobulin format
US9401875B2 (en)	2012-06-01	2016-07-26	Nippon Telegraph And Telephone Corporation	Packet transfer processing method and packet transfer processing device
US9580486B2 (en)	2013-03-14	2017-02-28	Amgen Inc.	Interleukin-2 muteins for the expansion of T-regulatory cells
LT3083681T (en)*	2013-12-20	2020-11-25	Neurimmune Holding Ag	Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor
US9300829B2 (en)	2014-04-04	2016-03-29	Canon Kabushiki Kaisha	Image reading apparatus and correction method thereof
TWI711631B (en)*	2015-01-28	2020-12-01	愛爾蘭商普羅佘納生物科技有限公司	Anti-transthyretin antibodies
WO2017083604A1 (en)	2015-11-12	2017-05-18	Amgen Inc.	Triazine mediated pharmacokinetic enhancement of therapeutics
WO2019070901A1 (en)	2017-10-04	2019-04-11	Amgen Inc.	Transthyretin immunoglobulin fusions

2020
- 2020-07-06SGSG11202112762TApatent/SG11202112762TA/enunknown
- 2020-07-06EPEP20745438.0Apatent/EP3997112A1/enactivePending
- 2020-07-06USUS17/624,824patent/US20220324924A1/enactivePending
- 2020-07-06WOPCT/US2020/040873patent/WO2021007150A1/ennot_activeCeased
- 2020-07-06KRKR1020227003259Apatent/KR20220032065A/enactivePending
- 2020-07-06CACA3140208Apatent/CA3140208A1/enactivePending
- 2020-07-06AUAU2020310851Apatent/AU2020310851A1/enactivePending
- 2020-07-06JPJP2022500558Apatent/JP7695925B2/enactiveActive
- 2020-07-06MXMX2021015976Apatent/MX2021015976A/enunknown
- 2020-07-06CNCN202080049750.1Apatent/CN114127125B/enactiveActive

Also Published As

Publication number	Publication date
KR20220032065A (en)	2022-03-15
WO2021007150A1 (en)	2021-01-14
MX2021015976A (en)	2022-02-10
CA3140208A1 (en)	2021-01-14
JP7695925B2 (en)	2025-06-19
JP2022540089A (en)	2022-09-14
CN114127125B (en)	2025-01-14
US20220324924A1 (en)	2022-10-13
EP3997112A1 (en)	2022-05-18
AU2020310851A1 (en)	2021-12-09
CN114127125A (en)	2022-03-01

Publication	Publication Date	Title
SG11202106214YA (en)	2021-07-29	Novel anti-ccr8 antibody
IL280780A (en)	2021-04-29	Anti-tigit antibodies
IL292727A (en)	2022-07-01	Multispecific antibody
SG11202009361PA (en)	2020-10-29	Her3 antigen-binding molecules
SG11202012360YA (en)	2021-01-28	Anti-il36r antibodies
IL279352A (en)	2021-01-31	Il-11ra antibodies
IL278010A (en)	2020-11-30	Galectin-10 antibodies
IL282756A (en)	2021-06-30	Humanized anti-sirpα antibodies
SG11202007735TA (en)	2020-09-29	Anti-her2 antibodies
IL277030A (en)	2020-10-29	Antibodies
GB202110263D0 (en)	2021-09-01	Anti-btla antibodies
IL279823A (en)	2021-03-01	Humanized antibodies against psma
IL281594A (en)	2021-05-31	Anti-klrg1 antibodies
SG11202112762TA (en)	2021-12-30	Multispecific transthyretin immunoglobulin fusions
GB201806084D0 (en)	2018-05-30	Antibodies
SG11202003114UA (en)	2020-05-28	Transthyretin immunoglobulin fusions
HK40073808A (en)	2022-12-23	Multispecific transthyretin immunoglobulin fusions
GB201720028D0 (en)	2018-01-17	Antigen-binding molecule format
HK40032551A (en)	2021-03-26	Transthyretin immunoglobulin fusions
IL282062A (en)	2021-05-31	Vinaigrette
GB201819952D0 (en)	2019-01-23	Antibodies
GB201817309D0 (en)	2018-12-05	Antibodies
GB201817311D0 (en)	2018-12-05	Antibodies
GB201817312D0 (en)	2018-12-05	Antibodies
GB201817313D0 (en)	2018-12-05	Antibodies

Movatterモバイル変換

SG11202112762TA - Multispecific transthyretin immunoglobulin fusions - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=71784719

Family Applications (1)

Country Status (10)

Families Citing this family (2)

Family Cites Families (32)

Also Published As

Similar Documents